Does Rallies show 13F holders for KRYS?

Yes. Rallies tracks hedge fund and 13F ownership data for KRYS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is KRYS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KRYS. It does not provide personalized investment advice.

KRYS (Krystal Biotech, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Krystal Biotech, Inc. Common Stock (KRYS) is a publicly traded Healthcare sector company. As of May 20, 2026, KRYS trades at $296.05 with a market cap of $8.60B and a P/E ratio of 38.58. KRYS moved +3.00% today. Year to date, KRYS is +23.43%; over the trailing twelve months it is +129.62%. Its 52-week range spans $122.80 to $319.48. Analyst consensus is strong buy with an average price target of $316.00. Rallies surfaces KRYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns KRYS stock?

Hedge funds tracked by Rallies that own KRYS include Redmile Group, Orbimed Advisors, Bridgewater Associates, Centerbook Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Krystal Biotech, Inc. Common Stock.

KRYS Key Metrics

Key financial metrics for KRYS
Metric	Value
Price	$296.05
Market Cap	$8.60B
P/E Ratio	38.58
EPS	$7.75
Dividend Yield	0.00%
52-Week High	$319.48
52-Week Low	$122.80
Volume	170.35K
Avg Volume	0
Revenue (TTM)	$417.30M
Net Income	$225.03M
Gross Margin	0.00%

Top Hedge Funds Holding KRYS

Redmile Group holds 673.50K shares of KRYS, changed -0.62% as of Mar 31, 2026.
Orbimed Advisors holds 69.10K shares of KRYS, changed -42.32% as of Mar 31, 2026.
Bridgewater Associates holds 46.37K shares of KRYS, changed +362.98% as of Mar 31, 2026.
Centerbook Partners holds 3.43K shares of KRYS, changed -32.11% as of Sep 30, 2025.
Farallon Capital holds 1.00K shares of KRYS, changed -50.00% as of Mar 31, 2026.

Latest KRYS News

Krystal Biotech jumps as Q1 VYJUVEK revenue hits $116.4M, pipeline catalysts build — May 5, 2026
Krystal Biotech drops as investors digest Q1 update despite $116.4M VYJUVEK revenue — May 4, 2026
Krystal Biotech Logs 32% VYJUVEK Revenue Growth, Strengthens Pipeline with KB803 Enrollment — May 4, 2026
Krystal Biotech to Unveil KB409/410 PCD Data and KB407, KB707 Trial Updates — Apr 30, 2026
Krystal Biotech drops as traders trim exposure ahead of early-May earnings report — Apr 29, 2026

Recent KRYS Insider Trades

Krishnan Suma sold 407 (~$104.73K) on Mar 4, 2026.
Krishnan Suma sold 589 (~$152.28K) on Mar 4, 2026.
Krishnan Suma sold 668 (~$173.42K) on Mar 4, 2026.

KRYS Analyst Consensus

10 analysts cover KRYS: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $316.00.

Common questions about KRYS

Who owns KRYS stock?: Hedge funds tracked by Rallies that own KRYS include Redmile Group, Orbimed Advisors, Bridgewater Associates, Centerbook Partners, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Krystal Biotech, Inc. Common Stock.
Does Rallies show 13F holders for KRYS?: Yes. Rallies tracks hedge fund and 13F ownership data for KRYS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is KRYS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KRYS. It does not provide personalized investment advice.